

Index to volume 60

Author index

A

- Aarbakke J (*see* Park-Hah et al). 1996;60:68-74
 Abernethy DR, Woosley RL. 1997 ASCPT Clinical Pharmacology Curriculum Review Course. 1996;60:699
 — (*see* Lipsitz et al). 1996;60:461-71
 Abiose A (*see* Grossmann et al). 1996;60:554-60
 Abrahamsson B (*see* Lindahl et al). 1996;60:493-503
 Alm C (*see* Carrillo et al). 1996;60:183-90
 Alván G (*see* Wakelkamp et al). 1996;60:75-88
 Ameer B, Weintraub RA, Johnson JV, Yost RA, Rouseff RL. Flavanone absorption after naringin, hesperidin, and citrus administration. 1996;60:34-40
 Anderson GD, Yau MK, Gidal BE, Harris SJ, Levy RH, Lai AA, Wolf KB, Wargin WA, Dren AT. Bidirectional interaction of valproate and lamotrigine in healthy subjects. 1996;60:145-56
 Andriani A (*see* De Cesaris et al). 1996;60:472-8
 Apseloff G, Swayne JK, Gerber N. Medical histories may be unreliable in screening volunteers for clinical trials. 1996;60:353-6
 Arendt-Nielsen L (*see* Poulsen et al). 1996;60:636-44
 Arnold JMO (*see* Bailey et al). 1996;60:25-33
 Asthana S, Greig NH, Holloway HW, Raffaele KC, Berardi A, Schapiro MB, Rapoport SI, Soncrant TJ. Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease. 1996;60:276-82
 Atkinson AJ Jr. A message from the president—come to San Diego, California, March 5-8, 1997. 1996;60:699
 —, Nordstrom K. The challenge of in-hospital medication use: an opportunity for clinical pharmacology. 1996;60:363-7 (Commentary)
 Atteneder M (*see* Thalhammer et al). 1996;60:645-50
 Awni WM (*see* Wong et al). 1996;60:48-53

B

- Baggott MJ (*see* Mendelson et al). 1996;60:105-14
 Bailey DG, Bend JR, Arnold JMO, Tran LT, Spence JD. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. 1996;60:25-33
 Balboa B (*see* Serrano et al). 1996;60:589-92
 Balian JD (*see* Marinac et al). 1996;60:138-44
 Bank AJ (*see* Rector et al). 1996;60:667-74
 Barbhaiya RH (*see* Knupp et al). 1996;60:535-42
 — (*see* Vachharajani et al). 1996;60:283-94
 Barr DM (*see* Paine et al). 1996;60:14-24
 Bartoli E (*see* Faedda et al). 1996;60:561-7
 — (*see* Faedda et al). 1996;60:576-81
 Bateman DN (*see* Hartigan-Go et al). 1996;60:89-98
 — (*see* Hartigan-Go et al). 1996;60:543-53
 Bélanger PM (*see* Hamelin et al). 1996;60:512-21
 Bend JR (*see* Bailey et al). 1996;60:25-33
 Benowitz N (*see* Gries et al). 1996;60:385-95
 Berardi A (*see* Asthana et al). 1996;60:276-82
 Bertilsson L (*see* Carrillo et al). 1996;60:183-90
 Bertocchi F (*see* De Cesaris et al). 1996;60:472-8
 Bigelow GE (*see* Strain et al). 1996;60:206-17
 Birnboeck H (*see* Weber et al). 1996;60:124-37
 Bjornsson TD (*see* Hcllriegel et al). 1996;60:601-7 (Commentary)
 Blaschke TF (*see* Grossmann et al). 1996;60:554-60
 Blouin RA (*see* Chen et al). 1996;60:522-34
 Blumer JL (*see* Sullivan et al). 1996;60:405-13
 — (*see* Sullivan et al). 1996;60:414-23
 — (*see* Sullivan et al). 1996;60:424-34

- Bochner F (*see* Capon et al). 1996;60:295-307
 Bodin F (*see* Corea et al). 1996;60:341-6
 Bonfantino MV (*see* De Cesaris et al). 1996;60:472-8
 Bosincu L (*see* Faedda et al). 1996;60:561-7
 — (*see* Faedda et al). 1996;60:576-81
 Breyer S (*see* Thalhammer et al). 1996;60:645-50
 Brøsen K (*see* Poulsen et al). 1996;60:636-44
 Brown HV (*see* Schneider et al). 1996;60:568-75
 Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. 1996;60:8-13
 Brune K (*see* Lötsch et al). 1996;60:316-25
 Burggraaf J (*see* Visser et al). 1996;60:452-60
 Burgmann H (*see* Thalhammer et al). 1996;60:645-50

C

- Caballero D (*see* Fernández de Gatta et al). 1996;60:332-40
 Cabiac MD (*see* Humbert et al). 1996;60:265-75
 Canal V (*see* Fernández de Gatta et al). 1996;60:332-40
 Canal N, Imbimbo BP, Eptastigmine Study Group. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. 1996;60:218-28
 Cantilena LR Jr, Woosley RL. Survey of clinical pharmacology training in the United States and Canada. 1996;60:1-7
 Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. 1996;60:295-307
 Caraco Y, Lagerstrom PO, Wood AJJ. Ethnic and genetic determinants of omeprazole disposition and effect. 1996;60:157-67
 —, Wilkinson GR, Wood AJJ. Differences between white subjects and Chinese subjects on the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. 1996;60:396-404
 Cardoni O (*see* Corea et al). 1996;60:341-6
 Carignan G (*see* Laganière et al). 1996;60:255-64
 Carrier K (*see* Laganière et al). 1996;60:255-64
 Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodríguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. 1996;60:183-90
 Cavallo A (*see* De Cesaris et al). 1996;60:472-8
 Cavanaugh J (*see* Wong et al). 1996;60:48-53
 Chang WH (*see* Lane et al). 1996;60:696-8 (Letter)
 Chen L, Mohr SN, Yang CS. Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of water-cress by human volunteers. 1996;60:651-60
 Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. 1996;60:522-34
 Chiba K (*see* Kubota et al). 1996;60:661-6
 Chin C (*see* Lerman et al). 1996;60:485-92
 Choi KH (*see* Park-Hah et al). 1996;60:68-74
 Chou WH (*see* Chen et al). 1996;60:522-34
 Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. 1996;60:687-95
 Coakley DF (*see* Knupp et al). 1996;60:535-42
 Cohen AF (*see* van Griensven et al). 1996;60:504-11
 — (*see* Visser et al). 1996;60:452-60

I

- Iga T (see Kotaki et al). 1996;60:229-35
Imbimbo BP (see Canal et al). 1996;60:218-28
Innocenti P (see Corea et al). 1996;60:341-6
Ishizaki T (see Kubota et al). 1996;60:661-6
Ito K (see Kotaki et al). 1996;60:229-35
Iversen E (see Nørregaard et al). 1996;60:679-86

J

- Jakobsen HB (see Nørregaard et al). 1996;60:679-86
Jalava KM (see Neuvonen and Jalava). 1996;60:54-61
Jiménez CM (see Serrano et al). 1996;60:589-92
Johnson JV (see Ameer et al). 1996;60:34-40
Jones CR (see Weber et al). 1996;60:124-37
Jones DR, Gorski JC, Haehner BD, O'Mara EM Jr, Hall SD.
Determination of cytochrome P450 3A4/5 activity in vivo with
dextromethorphan *N*-demethylation. 1996;60:374-84
Jones RT (see Mendelson et al). 1996;60:105-14
Jonkman JHG (see Weber et al). 1996;60:124-37
Jørgensen S (see Nørregaard et al). 1996;60:679-86

K

- Kaga K (see Kotaki et al). 1996;60:229-35
Kaufmann GR, Wenk M, Taeschner W, Peterli B, Gyr K, Meyer
UA, Haefeli WE. *N*-Acetyltransferase 2 polymorphism in patients
infected with human immunodeficiency virus. 1996;60:62-7
Kaul S (see Knupp et al). 1996;60:535-42
Kelley-Gagnon M (see Lipsitz et al). 1996;60:461-71
Kennedy BP (see Mills et al). 1996;60:99-104
Kerry N (see Capon et al). 1996;60:295-307
Keung ACF (see Lerman et al). 1996;60:485-92
Kiely DK (see Lipsitz et al). 1996;60:461-71
Klemetsdal B (see Park-Hah et al). 1996;60:68-74
Kluft K (see van Griensven et al). 1996;60:504-11
Knupp CA, Hak LJ, Coakley DF, Falk RJ, Wagner BE, Raasch RH,
van der Horst CM, Kaul S, Barbhuiya RH, Dukes GE. Disposition
of didanosine in HIV-seropositive patients with normal renal
function or chronic renal failure: influence of hemodialysis and
continuous ambulatory peritoneal dialysis. 1996;60:535-42
Knutson L (see Lindahl et al). 1996;60:493-503
Knutson TW (see Lindahl et al). 1996;60:493-503
Kobal G (see Lötsch et al). 1996;60:316-25
Kotaki H, Tayama N, Ito K, Mitomi N, Tezuka K, Kaga K, Sawada
Y, Iga T. Safe and effective topical application dose of lidocaine
for surgery with laryngomicroscopy. 1996;60:229-35
Krejcy K (see Schmetterer et al). 1996;60:199-205
Kroon R (see van Griensven et al). 1996;60:504-11
Kubo SH (see Rector et al). 1996;60:667-74
Kubota T, Chiba K, Ishizaki T. Genotyping of *S*-mephenytoin 4'-
hydroxylation in an extended Japanese population. 1996;60:661-
6
Kunze KL (see Paine et al). 1996;60:14-24

L

- Laganière S, Davies RF, Carignan G, Foris K, Goernert L, Carrier
K, Pereira C, McGilveray I. Pharmacokinetic and pharmacody-
namic interactions between diltiazem and quinidine. 1996;
60:255-64
Lagerstrom PO (see Caraco et al). 1996;60:157-67
Lai AA (see Anderson et al). 1996;60:145-56
Lai MD (see Tseng et al). 1996;60:177-82
Lai ML (see Tseng et al). 1996;60:177-82
Lamontanara G (see De Cesaris et al). 1996;60:472-8
Lane HY, Deng HC, Huang SM, Hu WH, Chang WH, Hu OYP.
Low frequency of dextromethorphan *O*-demethylation deficiency
in a Chinese population. 1996;60:696-8 (Letter)
Lavène D (see Humbert et al). 1996;60:265-75

- Lawson-Matthew P (see Morice et al). 1996;60:675-8
LeBel M (see Hamelin et al). 1996;60:512-21
Lennemäs H (see Lindahl et al). 1996;60:493-503
Lerman J, Sims C, Sikich N, Gow R, Chin C, Dempsey E, Howard
DR, Keung ACF. Pharmacokinetics of the active metabolite
(MDL 74,156) of dolasetron mesylate after oral or intravenous
administration to anesthetized children. 1996;60:485-92
Levy RH (see Anderson et al). 1996;60:145-56
Liebson IA (see Strain et al). 1996;60:206-17
Liendo C, Ghali JK, Graves SW. A new interference in some
digoxin assays: anti-murine heterophilic antibodies. 1996;60:593-
8
Lin KA (see Rector et al). 1996;60:667-74
Lindahl A, Sandström R, Ungell AL, Abrahamsson B, Knutson TW,
Knutson L, Lennemäs H. Jejunal permeability and hepatic extrac-
tion of fluvastatin in humans. 1996;60:493-503
Linder L (see Strobel et al). 1996;60:435-43
Linnet K, Wiborg O. Steady-state serum concentrations of the neu-
roleptic perphenazine in relation to CYP2D6 genetic polymor-
phism. 1996;60:41-7
Lipsitz LA, Connelly CM, Kelley-Gagnon M, Kiely DK, Abernethy
D, Waksmonski C. Cardiovascular adaptation to orthostatic stress
during vasodilator therapy. 1996;60:461-71
Logan AG (see Feldman et al). 1996;60:444-51
Lötsch J, Stockmann A, Kobal G, Brune K, Waibel R, Schmidt N,
Geisslinger G. Pharmacokinetics of morphine and its glu-
curonides after intravenous infusion of morphine and morphine-
6-glucuronide in healthy volunteers. 1996;60:316-25
Lunell E (see Vanakoski et al). 1996;60:308-15
Lüscher TF (see Strobel et al). 1996;60:435-43
Lysaa R (see Park-Hah et al). 1996;60:68-74

M

- Mandema JW, Stanski DR. Population pharmacodynamic model
for ketorolac analgesia. 1996;60:619-35
Mao Z (see Chen et al). 1996;60:522-34
Marinac JS, Balian JD, Foxworth JW, Willis SK, Daus JC, Owen
R, Flockhart DA. Determination of CYP2C19 phenotype in black
Americans with omeprazole: correlation with genotype.
1996;60:138-44
Marsh CL (see Paine et al). 1996;60:14-24
Mårtensson E (see Hartigan-Go et al). 1996;60:543-53
Martin WL (see Chen et al). 1996;60:522-34
Mayer G (see Thalhammer et al). 1996;60:645-50
McGilveray I (see Laganière et al). 1996;60:255-64
McVicar JP (see Paine et al). 1996;60:14-24
Meek QC (see Chen et al). 1996;60:522-34
Meilenbrock S (see Corea et al). 1996;60:341-6
Melby AK (see Mendelson et al). 1996;60:105-14
Mendelson J, Jones RT, Fernandez I, Welm S, Melby AK,
Baggott MJ. Buprenorphine and naloxone interactions in opiate-
dependent volunteers. 1996;60:105-14
Meyer FP, Tröger U, Röhl FW. Adverse nondrug reactions: an
update. 1996;60:347-52
Meyer UA (see Kaufmann et al). 1996;60:62-7
Mikkelsen KL (see Nørregaard et al). 1996;60:679-86
Mikus G (see Capon et al). 1996;60:295-307
Mills PJ, Ziegler MG, Nelesen RA, Kennedy BP. The effects of the
menstrual cycle, race, and gender on adrenergic receptors and
agonists. 1996;60:99-104
Mitomi N (see Kotaki et al). 1996;60:229-35
Mohr SN (see Chen et al). 1996;60:651-60
Morgenthien EA (see Vachharajani et al). 1996;60:283-94
Morice AH, Morris D, Lawson-Matthew P. A comparison of nebu-
lized budesonide with oral prednisolone in the treatment of exac-
erbations of obstructive pulmonary disease. 1996;60:675-8
Morris D (see Morice et al). 1996;60:675-8
Mullen KA (see Rector et al). 1996;60:667-74
Muller LM (see Visser et al). 1996;60:452-60

- Myers CM (see Sullivan et al). 1996;60:405-13
— (see Sullivan et al). 1996;60:414-23
— (see Sullivan et al). 1996;60:424-34

N

- Neill JR (see Chen et al). 1996;60:522-34
Nelesen RA (see Mills et al). 1996;60:99-104
Nelson SD (see Slattery et al). 1996;60:241-6 (Commentary)
Nelson TF (see Gosse et al). 1996;60:608-18 (Commentary)
Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. 1996;60:54-61
—, Varhe A, Olkkola KT. The effect of ingestion time interval on the interaction between itraconazole and triazolam. 1996;60:326-31
Nordstrom K (see Atkinson and Nordstrom). 1996;60:363-7 (Commentary)
Nørregaard J, Jørgensen S, Mikkelsen KL, Tønnesen P, Iversen E, Sørensen T, Sjøberg B, Jakobsen HB. The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain. 1996;60:679-86
Nyberg G (see Hartigan-Go et al). 1996;60:543-53

O

- Olkkola KT (see Neuvonen et al). 1996;60:326-31
Olmstead RE (see Schneider et al). 1996;60:568-75
O'Mara EM Jr (see Jones et al). 1996;60:374-84
Owen R (see Marinac et al). 1996;60:138-44

P

- Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE. First-pass metabolism of midazolam by the human intestine. 1996;60:14-24
Paintaud G (see Wakelkamp et al). 1996;60:75-88
Paquet F (see Hamelin et al). 1996;60:512-21
Park SS (see Zhou et al). 1996;60:191-8
Park-Hah JO, Klemetsdal B, Lysaa R, Choi KH, Aarbakke J. Thiopurine methyltransferase activity in a Korean population sample of children. 1996;60:68-74
Peeters PAM (see Weber et al). 1996;60:124-37
Pereira C (see Laganière et al). 1996;60:255-64
Perkins JD (see Paine et al). 1996;60:14-24
Peter K, Gambertoglio JG. Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus. 1996;60:168-76
Peterli B (see Kaufmann et al). 1996;60:62-7
Pihlstrom B (see Zhou et al). 1996;60:191-8
Pirisi M (see Faedda et al). 1996;60:561-7
— (see Faedda et al). 1996;60:576-81
Porcellati C (see Corea et al). 1996;60:341-6
Posvar EL (see Cilla et al). 1996;60:687-95
Poulsen L, Arendt-Nielsen L, Brøsen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. 1996;60:636-44
Preston KL (see Strain et al). 1996;60:206-17
Provvidenza M (see Corea et al). 1996;60:341-6
Putz D (see Thalhammer et al). 1996;60:645-50

R

- Raasch RH (see Knupp et al). 1996;60:535-42
Raffaie KC (see Asthana et al). 1996;60:276-82
Ranieri G (see De Cesaris et al). 1996;60:472-8
Rapoport SI (see Asthana et al). 1996;60:276-82
Ray WA (see Brown et al). 1996;60:8-13
Rector TS, Bank AJ, Tschumperlin LK, Mullen KA, Lin KA, Kubo SH. Abnormal desmopressin-induced forearm vasodilatation in patients with heart failure: dependence on nitric oxide synthase activity. 1996;60:667-74

- Reele SB. Publishing Summary Basis of Approval. 1996;60:357 (Letter)
Rodríguez I (see Carrillo et al). 1996;60:183-90
Röhl FW (see Meyer et al). 1996;60:347-52
Rosenkranz AR (see Thalhammer et al). 1996;60:645-50
Rouseff RL (see Ameer et al). 1996;60:34-40

S

- Sandström R (see Lindahl et al). 1996;60:493-503
San Miguel JF (see Fernández de Gatta et al). 1996;60:332-40
Satta A (see Faedda et al). 1996;60:561-7
— (see Faedda et al). 1996;60:576-81
Sawada Y (see Kotaki et al). 1996;60:229-35
Schapiro MB (see Asthana et al). 1996;60:276-82
Schmaldienst S (see Thalhammer et al). 1996;60:645-50
Schmetterer L, Wolzt M, Krejcy K, Graselli U, Findl O, Eichler HG, Singer EA. Cerebral and ocular hemodynamic effects of sumatriptan in the nitroglycerin headache model. 1996;60:199-205
Schmidt N (see Lötsch et al). 1996;60:316-25
Schmidt ND (see Feldman et al). 1996;60:444-51
Schmitt R (see Weber et al). 1996;60:124-37
Schneider NG, Olmstead RE, Steinberg C, Sloan K, Daims RM, Brown HV. Efficacy of buspirone in smoking cessation: a placebo-controlled trial. 1996;60:568-75
Schoemaker RC (see van Griensven et al). 1996;60:504-11
— (see Visser et al). 1996;60:452-60
Schwartz JB. A message from the Scientific Program Committee chairperson: 1997 annual meeting—March 5-7 (ASCP), March 8 (ASCP/ASPET). 1996;60:115
Sedman AJ (see Cilla et al). 1996;60:687-95
Seppälä T (see Vanakoski et al). 1996;60:308-15
Serrano JS, Jiménez CM, Serrano MI, Balboa B. A possible interaction of potential clinical interest between digoxin and acarbose. 1996;60:589-92
Serrano MI (see Serrano et al). 1996;60:589-92
Shen DD (see Paine et al). 1996;60:14-24
Shi H (see Wong et al). 1996;60:48-53
Shyu WC (see Vachharajani et al). 1996;60:283-94
Sievi E (see Vanakoski et al). 1996;60:308-15
Sikich N (see Lerman et al). 1996;60:485-92
Simper D (see Strobel et al). 1996;60:435-43
Sims C (see Lerman et al). 1996;60:485-92
Sindrup SH (see Poulsen et al). 1996;60:636-44
Singer EA (see Schmetterer et al). 1996;60:199-205
Slattery JT, Nelson SD, Thummel KE. The complex interaction between ethanol and acetaminophen. 1996;60:241-6 (Commentary)
Sloan K (see Schneider et al). 1996;60:568-75
Snowden M (see Brown et al). 1996;60:8-13
Sjøberg B (see Nørregaard et al). 1996;60:679-86
Somogyi AA (see Capon et al). 1996;60:295-307
Soncrant TT (see Asthana et al). 1996;60:276-82
Sørensen T (see Nørregaard et al). 1996;60:679-86
Spence JD (see Bailey et al). 1996;60:25-33
Stanski DR (see Mandema and Stanski). 1996;60:619-35
Steinberg C (see Schneider et al). 1996;60:568-75
Stockmann A (see Lötsch et al). 1996;60:316-25
Strain EC, Preston KL, Liebson IA, Bigelow GE. Opioid antagonist effects of dezocine in opioid-dependent humans. 1996;60:206-17
Strobel WM, Lüscher TF, Simper D, Linder L, Haefeli WE. Substance P in human hand veins in vivo: tolerance, efficacy, potency, and mechanism of venodilator action. 1996;60:435-43
Stuurman T (see van Griensven et al). 1996;60:504-11
Sullivan J (see Corea et al). 1996;60:341-6
Sullivan JE, Witte MK, Yamashita TS, Myers CM, Blumer JL. Analysis of the variability in the pharmacokinetics and pharma-

codynamics of bumetanide in critically ill infants. 1996;60:414-23

_____, _____, _____, _____, _____. Dose-ranging evaluation of bumetanide pharmacodynamics in critically ill infants. 1996;60:424-34

_____, _____, _____, _____. Pharmacokinetics of bumetanide in critically ill infants. 1996;60:405-13

Svensson JO (see Carrillo et al). 1996;60:183-90

Swayne JK (see Apseloff et al). 1996;60:353-6

T

Taeschner W (see Kaufmann et al). 1996;60:62-7

Tangphao O (see Grossmann et al). 1996;60:554-60

Tayama N (see Kotaki et al). 1996;60:229-35

Tezuka K (see Kotaki et al). 1996;60:229-35

Thalhammer F, Schmaldienst S, Elmenyawi I, Atteneder M, Burgmann H, Hollenstein U, Georgopoulos A, Graninger W, Putz D, Rosenkranz AR, Mayer G, Hörl WH, Breyer S. Multiple-dose pharmacokinetics of cefpirome in long-term hemodialysis with high-flux membranes. 1996;60:645-50

Thomas SHL (see Hartigan-Go et al). 1996;60:89-98

_____. (see Hartigan-Go et al). 1996;60:543-53

Thummel KE (see Paine et al). 1996;60:14-24

_____. (see Slattery et al). 1996;60:241-6 (Commentary)

Tønnesen P (see Nørregaard et al). 1996;60:679-86

Tran LT (see Bailey et al). 1996;60:25-33

Tröger U (see Meyer et al). 1996;60:347-52

Tschumperlin LK (see Rector et al). 1996;60:667-74

Tseng CY, Wang SL, Lai MD, Lai ML, Huang Jd. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. 1996;60:177-82

Turgeon J (see Hamelin et al). 1996;60:512-21

U

Ungell AL (see Lindahl et al). 1996;60:493-503

V

Vachharajani NN, Shyu WC, Garnett WR, Morgenthien EA, Barbhuiya RH. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment. 1996;60:283-94

Vallée F (see Hamelin et al). 1996;60:512-21

Vanakoski J, Seppälä T, Sievi E, Lunell E. Exposure to high ambient temperature increases absorption and plasma concentrations of transdermal nicotine. 1996;60:308-15

van der Horst CM (see Knupp et al). 1996;60:535-42

van Griensven JMT, Huisman LGM, Stuurman T, Dooijewaard G, Kroon R, Schoemaker RC, Kluft K, Cohen AF. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator. 1996;60:504-11

van Marle SP (see Weber et al). 1996;60:124-37

Varhe A (see Neuvonen et al). 1996;60:326-31

Verotta D (see Gries et al). 1996;60:385-95

Visser WH, Burggraaf J, Muller LM, Schoemaker RC, Fowler PA, Cohen AF, Ferrari MD. Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. 1996;60:452-60

W

Wagner BE (see Knupp et al). 1996;60:535-42

Waibel R (see Lötsch et al). 1996;60:316-25

Wakelkamp M, Alván G, Gabriëlsso J, Paintaud G. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. 1996;60:75-88

Waksmanski C (see Lipsitz et al). 1996;60:461-71

Wang SL (see Tseng et al). 1996;60:177-82

Wargin WA (see Anderson et al). 1996;60:145-56

Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PAM, Jonkman JHG, Jones CR. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. 1996;60:124-37

Wedlund PJ (see Chen et al). 1996;60:522-34

Wehbe TW, Warth JA. A case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole (1996;59:360-2). 1996;60:137 (Correction)

Weiner GJ (see Weiner and Weiner). 1996;60:247-54 (Commentary)

Weiner M, Weiner GJ. The kinetics and dynamics of responses to placebo. 1996;60:247-54 (Commentary)

Weinshilboum RM. A message from the Finance Committee chairperson. 1996;60:480

Weintraub RA (see Ameer et al). 1996;60:34-40

Welm S (see Mendelson et al). 1996;60:105-14

Wenk M (see Kaufmann et al). 1996;60:62-7

Whitfield LR (see Cilla et al). 1996;60:687-95

Wiborg O (see Linnet and Wiborg). 1996;60:41-7

Wilkinson GR (see Caraco et al). 1996;60:396-404

Willsie SK (see Marinac et al). 1996;60:138-44

Witte MK (see Sullivan et al). 1996;60:405-13

_____. (see Sullivan et al). 1996;60:414-23

_____. (see Sullivan et al). 1996;60:424-34

Wolf KB (see Anderson et al). 1996;60:145-56

Wolzt M (see Schmetterer et al). 1996;60:199-205

Wong SL, Cavanaugh J, Shi H, Awni WM, Granneman GR. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. 1996;60:48-53

Wood AJJ (see Caraco et al). 1996;60:157-67

_____. (see Caraco et al). 1996;60:396-404

Woosley RL (see Abernethy and Woosley). 1996;60:699

_____. (see Cantilena and Woosley). 1996;60:1-7

Wrighton SA (see Zhou et al). 1996;60:191-8

Y

Yamashita TS (see Sullivan et al). 1996;60:405-13

_____. (see Sullivan et al). 1996;60:414-23

_____. (see Sullivan et al). 1996;60:424-34

Yang CS (see Chen et al). 1996;60:651-60

Yau MK (see Anderson et al). 1996;60:145-56

Yost RA (see Ameer et al). 1996;60:34-40

Z

Zhou LX, Pihlstrom B, Hardwick JP, Park SS, Wrighton SA, Holtzman JL. Metabolism of phenytoin by the gingiva of normal humans: the possible role of reactive metabolites of phenytoin in the initiation of gingival hyperplasia. 1996;60:191-8

Ziegler MG (see Mills et al). 1996;60:99-104

Subject index

A

Abafilcon A

Abafilcon A (USAN List No. 387). 1996;60:484

Acetaminophen

The complex interaction between ethanol and acetaminophen (Slattery et al). 1996;60:241-6 (Commentary)

Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers (Chen et al). 1996;60:651-60

Acetyltransferase

N-Acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus (Kaufmann et al). 1996;60:62-7

Adefovir dipivoxil

Adefovir dipivoxil (USAN List No. 385). 1996;60:237

Administration, cutaneous

Exposure to high ambient temperature increases absorption and plasma concentrations of transdermal nicotine (Vanakoski et al). 1996;60:308-15

Administration, nasal

The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment (Vachharajani et al). 1996;60:283-94

Human pharmacokinetics of dihydroergotamine administered by nasal spray (Humbert et al). 1996;60:265-75

Administration, oral

Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children (Lerman et al). 1996;60:485-92

Administration, topical

Safe and effective topical application dose of lidocaine for surgery with laryngomicroscopy (Kotaki et al). 1996;60:229-35

Adverse drug reactions

Adverse nondrug reactions: an update (Meyer et al). 1996;60:347-52

African-Americans

Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema (Brown et al). 1996;60:8-13

Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype (Marinac et al). 1996;60:138-44

Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects (Elliott). 1996;60:582-8

Aged

Cardiovascular adaptation to orthostatic stress during vasodilator therapy (Lipsitz et al). 1996;60:461-71

Albumin

Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes (De Cesaris et al). 1996;60:472-8

Alcohol, ethyl

The complex interaction between ethanol and acetaminophen (Slattery et al). 1996;60:241-6 (Commentary)

Alpha-adrenergic receptors; see Receptors, adrenergic, alpha

Alzheimer's disease

Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease (Asthana et al). 1996;60:276-82

Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease (Canal et al). 1996;60:218-28

American Society for Clinical Pharmacology and Therapeutics

1997 ASCPT Clinical Pharmacology Curriculum Review Course (Abernethy and Woosley). 1996;60:699

Future meeting dates and sites. 1996;60:115, 236

A message from the Education Committee chairman (Gray). 1996;60:236

A message from the Ethics Committee chairman (Dunton). 1996;60:360

A message from the Finance Committee chairperson (Weinshilboum). 1996;60:480

A message from the president—come to San Diego, California, March 5-8, 1997 (Atkinson). 1996;60:699

A message from the Scientific Program Committee chairperson: 1997 annual meeting—March 5-7 (ASCPT), March 8 (ASCPT/ASPET) (Schwartz). 1996;60:115

Nominations for awards. 1996;60:358-9

Amitriptyline

Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics (Wong et al). 1996;60:48-53

Amlodipine

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine (Corea et al). 1996;60:341-6

Analgesics

The hypoalgesic effect of tramadol in relation to CYP2D6 (Poulsen et al). 1996;60:636-44

Population pharmacodynamic model for ketorolac analgesia (Mandema and Stanski). 1996;60:619-35

Angioneurotic edema

Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema (Brown et al). 1996;60:8-13

Angiotensin II

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine (Corea et al). 1996;60:341-6

Angiotensin-converting enzyme inhibitors

Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema (Brown et al). 1996;60:8-13

Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects (Elliott). 1996;60:582-8

Antibodies, heterophile

A new interference in some digoxin assays: anti-murine heterophilic antibodies (Liendo et al). 1996;60:593-8

Antibodies, monoclonal

Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994 (Gosse et al). 1996;60:608-18 (Commentary)

Antihypertensive agents

Reserpine: a tragic victim of myths, marketing, and fashionable prescribing (Fraser). 1996;60:368-73 (Commentary)

Aptiganel hydrochloride

Aptiganel hydrochloride (USAN List No. 387). 1996;60:483

Arcitumomab

Arcitumomab (USAN List No. 385). 1996;60:238

Arecoline

Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease (Asthana et al). 1996;60:276-82

Atorvastatin

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects (Cilla et al). 1996;60:687-95

Azelaic acid

Azelaic acid (USAN List No. 386). 1996;60:362

B

Becaplermin

Becaplermin (USAN List No. 384). 1996;60:117

Benazepril

Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes (De Cesaris et al). 1996;60:472-8

Berger's disease; see Glomerulonephritis, IgA

Beta-adrenergic receptors; see Receptors, adrenergic, beta

Bioavailability

Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies (Hellriegel et al). 1996;60:601-7 (Commentary)

Black Americans; see African-Americans

Books received

Books received. 1996;60:240

Bosentan

Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects (Weber et al). 1996;60:124-37

Brain

Cerebral and ocular hemodynamic effects of sumatriptan in the nitroglycerin headache model (Schmetterer et al). 1996;60:199-205

Budesonide

A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease (Morice et al). 1996;60:675-8

Bumetanide

Analysis of the variability in the pharmacokinetics and pharmacodynamics of bumetanide in critically ill infants (Sullivan et al). 1996;60:414-23

Dose-ranging evaluation of bumetanide pharmacodynamics in critically ill infants (Sullivan et al). 1996;60:424-34

Pharmacokinetics of bumetanide in critically ill infants (Sullivan et al). 1996;60:405-13

Buprenorphine

Buprenorphine and naloxone interactions in opiate-dependent volunteers (Mendelson et al). 1996;60:105-14

Buspirone

Efficacy of buspirone in smoking cessation: a placebo-controlled trial (Schneider et al). 1996;60:568-75

Butorphanol

The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment (Vachharajani et al). 1996;60:283-94

C

Cabergoline

Cabergoline (USAN List No. 386). 1996;60:361

Caffeine

The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain (Nørregaard et al). 1996;60:679-86

Canada

Survey of clinical pharmacology training in the United States and Canada (Cantilena and Woosley). 1996;60:1-7

Cardiotoxicity; see Heart, toxicity

Cefpirome

Multiple-dose pharmacokinetics of cefpirome in long-term hemodialysis with high-flux membranes (Thalhammer et al). 1996;60:645-50

Cerivastatin sodium

Cerivastatin sodium (USAN List No. 385). 1996;60:237

Child; see also Infant

Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children (Lerman et al). 1996;60:485-92

Thiopurine methyltransferase activity in a Korean population sample of children (Park-Hah et al). 1996;60:68-74

China

Differences between white subjects and Chinese subjects on the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole (Caraco et al). 1996;60:396-404

Ethnic and genetic determinants of omeprazole disposition and effect (Caraco et al). 1996;60:157-67

Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes (Tseng et al). 1996;60:177-82

Circadian rhythm

Chronopharmacokinetics of nicotine (Gries et al). 1996;60:385-95

Clinical pharmacology

The challenge of in-hospital medication use: an opportunity for clinical pharmacology (Atkinson and Nordstrom). 1996;60:363-7 (Commentary)

Survey of clinical pharmacology training in the United States and Canada (Cantilena and Woosley). 1996;60:1-7

Clinical trials

Adverse nondrug reactions: an update (Meyer et al). 1996;60:347-52

Factors often not considered before a multicenter trial is started (Hardy). 1996;60:121-3 (Commentary)

Medical histories may be unreliable in screening volunteers for clinical trials (Apseloff et al). 1996;60:353-6

Codeine

Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes (Tseng et al). 1996;60:177-82

Cognition

Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease (Canal et al). 1996;60:218-28

Commentaries

Commentaries. 1996;60:121-3, 241-54, 363-73

Continuous ambulatory peritoneal dialysis; see Dialysis

Correction

A case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole (Wehbe and Warth) (1996;59:360-2). 1996;60:137

Correspondence; see Letters

Costs and cost analysis

Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies (Fernández de Gatta et al). 1996;60:332-40

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry (Chen et al). 1996;60:522-34

Cough

Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects (Elliott). 1996;60:582-8

Critical illness

Analysis of the variability in the pharmacokinetics and pharmacodynamics of bumetanide in critically ill infants (Sullivan et al). 1996;60:414-23

Dose-ranging evaluation of bumetanide pharmacodynamics in critically ill infants (Sullivan et al). 1996;60:424-34

Pharmacokinetics of bumetanide in critically ill infants (Sullivan et al). 1996;60:405-13

Cyclophosphamide

Regression of Henoch-Schönlein disease with intensive immunosuppressive treatment (Faedda et al). 1996;60:576-81

Cytochrome P450

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry (Chen et al). 1996;60:522-34

Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype (Marinac et al). 1996;60:138-44

Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan *N*-demethylation (Jones et al). 1996;60:374-84

Differences between white subjects and Chinese subjects on the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole (Caraco et al). 1996;60:396-404

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity (Carrillo et al). 1996;60:183-90

The hypoalgesic effect of tramadol in relation to CYP2D6 (Poulsen et al). 1996;60:636-44

The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans (Capon et al). 1996;60:295-307

Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism (Linnert and Wiborg). 1996;60:41-7

D**Danaparoid sodium**

Danaparoid sodium (USAN List No. 387). 1996;60:484

Debrisoquin

The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin (Hamelin et al). 1996;60:512-21

Desmopressin

Abnormal desmopressin-induced forearm vasodilatation in patients with heart failure: dependence on nitric oxide synthase activity (Rector et al). 1996;60:667-74

Dextsotalol hydrochloride

Dextsotalol hydrochloride (USAN List No. 384). 1996;60:120

Dextromethorphan

Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan *N*-demethylation (Jones et al). 1996;60:374-84

The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans (Capon et al). 1996;60:295-307

Dezocine

Opioid antagonist effects of dezocine in opioid-dependent humans (Strain et al). 1996;60:206-17

Diabetes

Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes (De Cesaris et al). 1996;60:472-8

Dialysis

Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis (Knupp et al). 1996;60:535-42

Didanosine

Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis (Knupp et al). 1996;60:535-42

Diet

Dietary salt restriction increases vascular insulin resistance (Feldman et al). 1996;60:444-51

Digoxin

A new interference in some digoxin assays: anti-murine heterophilic antibodies (Liendo et al). 1996;60:593-8

A possible interaction of potential clinical interest between digoxin and acarbose (Serrano et al). 1996;60:589-92

Dihydroergotamine

Human pharmacokinetics of dihydroergotamine administered by nasal spray (Humbert et al). 1996;60:265-75

Diltiazem

Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine (Laganière et al). 1996;60:255-64

Divalproex sodium

Divalproex sodium (USAN List No. 386). 1996;60:362

Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics (Wong et al). 1996;60:48-53

Dolasetron

Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children (Lerman et al). 1996;60:485-92

Drug absorption

Exposure to high ambient temperature increases absorption and plasma concentrations of transdermal nicotine (Vanakoski et al). 1996;60:308-15

Flavanone absorption after naringin, hesperidin, and citrus administration (Ameer et al). 1996;60:34-40

Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies (Hellriegel et al). 1996;60:601-7 (Commentary)

Drug clearance

Chronopharmacokinetics of nicotine (Gries et al). 1996;60:385-95

Drug development

Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994 (Gosse et al). 1996;60:608-18 (Commentary)

Drug interactions

Bidirectional interaction of valproate and lamotrigine in healthy subjects (Anderson et al). 1996;60:145-56

Buprenorphine and naloxone interactions in opiate-dependent volunteers (Mendelson et al). 1996;60:105-14

The complex interaction between ethanol and acetaminophen (Slattery et al). 1996;60:241-6 (Commentary)

The effect of ingestion time interval on the interaction between itraconazole and triazolam (Neuvonen et al). 1996;60:326-31

Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics (Wong et al). 1996;60:48-53

Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice (Bailey et al). 1996;60:25-33

Flavanone absorption after naringin, hesperidin, and citrus administration (Ameer et al). 1996;60:34-40

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid (Neuvonen and Jalava). 1996;60:54-61

Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine (Laganière et al). 1996;60:255-64
A possible interaction of potential clinical interest between digoxin and acarbose (Serrano et al). 1996;60:589-92

Drug therapy

The challenge of in-hospital medication use: an opportunity for clinical pharmacology (Atkinson and Nordstrom). 1996;60:363-7 (Commentary)

Drug tolerance

Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration (Wakelkamp et al). 1996;60:75-88

E

Edrecolomab

Edrecolomab (USAN List No. 387). 1996;60:481

Education

Survey of clinical pharmacology training in the United States and Canada (Cantilena and Woosley). 1996;60:1-7

Eldacimibe

Eldacimibe (USAN List No. 386). 1996;60:362

Electrocardiography

Stereoselective cardiotoxic effects of terodiline (Hartigan-Go et al). 1996;60:89-98

Endothelins

Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects (Weber et al). 1996;60:124-37

Enzymes

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry (Chen et al). 1996;60:522-34

Ephedrine

The effect of ephedrine plus caffeine on smoking cessation and post-cessation weight gain (Nørregaard et al). 1996;60:679-86

Eptastigmine

Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease (Canal et al). 1996;60:218-28

Erythromycin

Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice (Bailey et al). 1996;60:25-33

Essential hypertension; see Hypertension

Ethanol; see Alcohol, ethyl

Ethnic factors

Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema (Brown et al). 1996;60:8-13
Differences between white subjects and Chinese subjects on the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole (Caraco et al). 1996;60:396-404

The effects of the menstrual cycle, race, and gender on adrenergic receptors and agonists (Mills et al). 1996;60:99-104

Ethnic and genetic determinants of omeprazole disposition and effect (Caraco et al). 1996;60:157-67

Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes (Tseng et al). 1996;60:177-82

Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population (Kubota et al). 1996;60:661-6

Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects (Elliott). 1996;60:582-8

Thiopurine methyltransferase activity in a Korean population sample of children (Park-Hah et al). 1996;60:68-74

Eye

Cerebral and ocular hemodynamic effects of sumatriptan in the nitroglycerin headache model (Schmetterer et al). 1996;60:199-205

F

Felodipine

Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice (Bailey et al). 1996;60:25-33

Flavanone

Flavanone absorption after naringin, hesperidin, and citrus administration (Ameer et al). 1996;60:34-40

Fluoxetine

The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin (Hamelin et al). 1996;60:512-21

Fluvastatin

Jejunal permeability and hepatic extraction of fluvastatin in humans (Lindahl et al). 1996;60:493-503

Fluvoxamine

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity (Carrillo et al). 1996;60:183-90

Food-drug interactions

Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers (Chen et al). 1996;60:651-60

Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice (Bailey et al). 1996;60:25-33

Flavanone absorption after naringin, hesperidin, and citrus administration (Ameer et al). 1996;60:34-40

Furosemide

Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration (Wakelkamp et al). 1996;60:75-88

G

Gender factors

The effects of the menstrual cycle, race, and gender on adrenergic receptors and agonists (Mills et al). 1996;60:99-104

Genotype

Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype (Marinac et al). 1996;60:138-44

Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes (Tseng et al). 1996;60:177-82

Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population (Kubota et al). 1996;60:661-6

Gingiva

Metabolism of phenytoin by the gingiva of normal humans: the possible role of reactive metabolites of phenytoin in the initiation of gingival hyperplasia (Zhou et al). 1996;60:191-8

Glomerulonephritis, IgA

Immunosuppressive treatment of Berger's disease (Faedda et al). 1996;60:561-7

Glucuronidation

Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers (Lötsch et al). 1996;60:316-25

Grapefruit juice

Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice (Bailey et al). 1996;60:25-33

Flavanone absorption after naringin, hesperidin, and citrus administration (Ameer et al). 1996;60:34-40

Guest reviewers

Guest reviewers. 1996;60:479

H**Hand**

Substance P in human hand veins in vivo: tolerance, efficacy, potency, and mechanism of venodilator action (Strobel et al). 1996;60:435-43

Headache

Cerebral and ocular hemodynamic effects of sumatriptan in the nitroglycerin headache model (Schmetterer et al). 1996;60:199-205

Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response (Visser et al). 1996;60:452-60

Heart, toxicity

Stereoselective cardiotoxic effects of terodiline (Hartigan-Go et al). 1996;60:89-98

Heart failure, congestive

Abnormal desmopressin-induced forearm vasodilatation in patients with heart failure: dependence on nitric oxide synthase activity (Rector et al). 1996;60:667-74

Hematologic diseases

Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies (Fernández de Gatta et al). 1996;60:332-40

Hemodialysis

Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis (Knupp et al). 1996;60:535-42

Multiple-dose pharmacokinetics of cefpirome in long-term hemodialysis with high-flux membranes (Thalhammer et al). 1996;60:645-50

Hemodynamics

Cerebral and ocular hemodynamic effects of sumatriptan in the nitroglycerin headache model (Schmetterer et al). 1996;60:199-205

Henoch-Schönlein disease; see Purpura, Schönlein-Henoch**Hepatic diseases; see Liver diseases****Hesperidin**

Flavanone absorption after naringin, hesperidin, and citrus administration (Ameer et al). 1996;60:34-40

Heterophilic antibodies; see Antibodies, heterophile**Hioxifilcon A**

Hioxifilcon A (USAN List No. 384). 1996;60:117

HIV

N-Acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus (Kaufmann et al). 1996;60:62-7

Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis (Knupp et al). 1996;60:535-42

Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus (Peter and Gambertoglio). 1996;60:168-76

Hospitals

The challenge of in-hospital medication use: an opportunity for clinical pharmacology (Atkinson and Nordstrom). 1996;60:363-7 (Commentary)

Human immunodeficiency virus; see HIV**Hydroxy-methylglutaryl coenzyme A**

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects (Cilla et al). 1996;60:687-95

Hyperplasia

Metabolism of phenytoin by the gingiva of normal humans: the possible role of reactive metabolites of phenytoin in the initiation of gingival hyperplasia (Zhou et al). 1996;60:191-8

Hypertension

Cardiovascular adaptation to orthostatic stress during vasodilator therapy (Lipsitz et al). 1996;60:461-71

Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes (De Cesaris et al). 1996;60:472-8

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine (Corea et al). 1996;60:341-6

I**Idoxifene**

Idoxifene (USAN List No. 389). 1996;60:700

Immune globulin intravenous pentetate

Immune globulin intravenous pentetate (USAN List No. 387). 1996;60:484

Immunosuppressive agents

Immunosuppressive treatment of Berger's disease (Faedda et al). 1996;60:561-7

Regression of Henoch-Schönlein disease with intensive immunosuppressive treatment (Faedda et al). 1996;60:576-81

Infant

Analysis of the variability in the pharmacokinetics and pharmacodynamics of bumetanide in critically ill infants (Sullivan et al). 1996;60:414-23

Dose-ranging evaluation of bumetanide pharmacodynamics in critically ill infants (Sullivan et al). 1996;60:424-34

Pharmacokinetics of bumetanide in critically ill infants (Sullivan et al). 1996;60:405-13

Infusions, intravenous

Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers (Lötsch et al). 1996;60:316-25

Injections, intravenous

Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration (Wakelkamp et al). 1996;60:75-88

Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children (Lerman et al). 1996;60:485-92

Insulin

Dietary salt restriction increases vascular insulin resistance (Feldman et al). 1996;60:444-51

Intestines

First-pass metabolism of midazolam by the human intestine (Paine et al). 1996;60:14-24

Intravenous infusions; see Infusions, intravenous**Intravenous injections; see Injections, intravenous****Irbesartan**

Irbesartan (USAN List No. 389). 1996;60:701

Itasetron

Itasetron (USAN List No. 387). 1996;60:483

Itraconazole

The effect of ingestion time interval on the interaction between itraconazole and triazolam (Neuvonen et al). 1996;60:326-31

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid (Neuvonen and Jalava). 1996;60:54-61

J**Japan**

Genotyping of 5-mephenytoin 4'-hydroxylation in an extended Japanese population (Kubota et al). 1996;60:661-6

Jejunum

Jejunal permeability and hepatic extraction of fluvastatin in humans (Lindahl et al). 1996;60:493-503

K

Ketorolac

Population pharmacodynamic model for ketorolac analgesia (Mandema and Stanski). 1996;60:619-35

Kidney failure, chronic

Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis (Knupp et al). 1996;60:535-42

Immunosuppressive treatment of Berger's disease (Faedda et al). 1996;60:561-7

Multiple-dose pharmacokinetics of cefpirome in long-term hemodialysis with high-flux membranes (Thalhammer et al). 1996;60:645-50

Korea

Thiopurine methyltransferase activity in a Korean population sample of children (Park-Hah et al). 1996;60:68-74

L

Lamotrigine

Bidirectional interaction of valproate and lamotrigine in healthy subjects (Anderson et al). 1996;60:145-56

Laryngomicroscopy

Safe and effective topical application dose of lidocaine for surgery with laryngomicroscopy (Kotaki et al). 1996;60:229-35

Latanoprost

Latanoprost (USAN List No. 388). 1996;60:599

Letters

Low frequency of dextromethorphan *O*-demethylation deficiency in a Chinese population (Lane et al). 1996;60:696-8

Publishing Summary Basis of Approval (Reele). 1996;60:357

Lidocaine

Safe and effective topical application dose of lidocaine for surgery with laryngomicroscopy (Kotaki et al). 1996;60:229-35

Liver

Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator (van Griensven et al). 1996;60:504-11

Jejunal permeability and hepatic extraction of fluvastatin in humans (Lindahl et al). 1996;60:493-503

Liver diseases

The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment (Vachharajani et al). 1996;60:283-94

Lobucavir

Lobucavir (USAN List No. 388). 1996;60:600

Lovastatin

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid (Neuvonen and Jalava). 1996;60:54-61

Lung diseases, obstructive

A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease (Morice et al). 1996;60:675-8

Lurtotecan dihydrochloride

Lurtotecan dihydrochloride (USAN List No. 388). 1996;60:600

M

Medical history-taking

Medical histories may be unreliable in screening volunteers for clinical trials (Apseloff et al). 1996;60:353-6

Menstruation

The effects of the menstrual cycle, race, and gender on adrenergic receptors and agonists (Mills et al). 1996;60:99-104

Mephenytoin

Genotyping of 5-mephenytoin 4'-hydroxylation in an extended Japanese population (Kubota et al). 1996;60:661-6

Microalbuminuria; see Albumin

Midazolam

First-pass metabolism of midazolam by the human intestine (Paine et al). 1996;60:14-24

Migraine

Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response (Visser et al). 1996;60:452-60

Milameline hydrochloride

Milameline hydrochloride (USAN List No. 388). 1996;60:599

Moexipril hydrochloride

Moexipril hydrochloride (USAN List No. 384). 1996;60:116

Monoclonal antibodies; see Antibodies, monoclonal

Morphine

Formation of morphine from codeine in Chinese subjects of different *CYP2D6* genotypes (Tseng et al). 1996;60:177-82

Morphine-induced venodilation in humans (Grossmann et al). 1996;60:554-60

Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers (Lötsch et al). 1996;60:316-25

N

Naloxone

Buprenorphine and naloxone interactions in opiate-dependent volunteers (Mendelson et al). 1996;60:105-14

Narcotics

Buprenorphine and naloxone interactions in opiate-dependent volunteers (Mendelson et al). 1996;60:105-14

Opioid antagonist effects of dezocine in opioid-dependent humans (Strain et al). 1996;60:206-17

Naringin

Flavanone absorption after naringin, hesperidin, and citrus administration (Ameer et al). 1996;60:34-40

Nasal spray; see Administration, nasal

Nicardipine

Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes (De Cesaris et al). 1996;60:472-8

Nicotine

Chronopharmacokinetics of nicotine (Gries et al). 1996;60:385-95
Exposure to high ambient temperature increases absorption and plasma concentrations of transdermal nicotine (Vanakoski et al). 1996;60:308-15

Nitric oxide

Abnormal desmopressin-induced forearm vasodilatation in patients with heart failure: dependence on nitric oxide synthase activity (Rector et al). 1996;60:667-74

Nitroglycerin

Cerebral and ocular hemodynamic effects of sumatriptan in the nitroglycerin headache model (Schmetterer et al). 1996;60:199-205

Nortriptyline

Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics (Wong et al). 1996;60:48-53

O

Obstructive lung diseases; see Lung diseases, obstructive

Omeprazole

Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype (Marinac et al). 1996;60:138-44

Differences between white subjects and Chinese subjects on the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole (Caraco et al). 1996;60:396-404

Ethnic and genetic determinants of omeprazole disposition and effect (Caraco et al). 1996;60:157-67

Opiates; see Narcotics

Opioids; see Narcotics

Oral administration; see Administration, oral

Orange juice

Flavanone absorption after naringin, hesperidin, and citrus administration (Ameer et al). 1996;60:34-40

Orbifiban acetate

Orbifiban acetate (USAN List No. 389). 1996;60:700

P**Palonosetron hydrochloride**

Palonosetron hydrochloride (USAN List No. 386). 1996;60:361

Pamaquesside

Pamaquesside (USAN List No. 385). 1996;60:238

Patient perception

The kinetics and dynamics of responses to placebo (Weiner and Weiner). 1996;60:247-54 (Commentary)

Peldesine

Peldesine (USAN List No. 385). 1996;60:238

Perphenazine

Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism (Linnet and Wiborg). 1996;60:41-7

Phenotype

Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype (Marinac et al). 1996;60:138-44

Phenytoin

Metabolism of phenytoin by the gingiva of normal humans: the possible role of reactive metabolites of phenytoin in the initiation of gingival hyperplasia (Zhou et al). 1996;60:191-8

Piclamilast

Piclamilast (USAN List No. 388). 1996;60:600

Piroxicam betadex

Piroxicam betadex (USAN List No. 389). 1996;60:702

Placebo

Efficacy of buspirone in smoking cessation: a placebo-controlled trial (Schneider et al). 1996;60:568-75

The kinetics and dynamics of responses to placebo (Weiner and Weiner). 1996;60:247-54 (Commentary)

Plasma

Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers (Chen et al). 1996;60:651-60

Exposure to high ambient temperature increases absorption and plasma concentrations of transdermal nicotine (Vanakoski et al). 1996;60:308-15

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid (Neuvonen and Jalava). 1996;60:54-61

Plasminogen activator, tissue-type

Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator (van Griensven et al). 1996;60:504-11

Polymorphism

N-Acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus (Kaufmann et al). 1996;60:62-7

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry (Chen et al). 1996;60:522-34

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity (Carrillo et al). 1996;60:183-90

The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans (Capon et al). 1996;60:295-307

Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism (Linnet and Wiborg). 1996;60:41-7

Population studies

Population pharmacodynamic model for ketorolac analgesia (Mandema and Stanski). 1996;60:619-35

Prednisolone

A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease (Morice et al). 1996;60:675-8

Prednisone

Regression of Henoch-Schönlein disease with intensive immunosuppressive treatment (Faedda et al). 1996;60:576-81

Priliximab

Priliximab (USAN List No. 387). 1996;60:481

Proteins

Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994 (Gosse et al). 1996;60:608-18 (Commentary)

Psychiatry

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry (Chen et al). 1996;60:522-34

Purpura, Schönlein-Henoch

Regression of Henoch-Schönlein disease with intensive immunosuppressive treatment (Faedda et al). 1996;60:576-81

Q**Quality of health care**

The challenge of in-hospital medication use: an opportunity for clinical pharmacology (Atkinson and Nordstrom). 1996;60:363-7 (Commentary)

Quiflapon sodium

Quiflapon sodium (USAN List No. 384). 1996;60:118

Quinidine

The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans (Capon et al). 1996;60:295-307

Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine (Laganière et al). 1996;60:255-64

R

Racial factors; see also Ethnic factors

The effects of the menstrual cycle, race, and gender on adrenergic receptors and agonists (Mills et al). 1996;60:99-104

Ractopamine hydrochloride

Ractopamine hydrochloride (USAN List No. 384). 1996;60:119

Raltitrexed

Raltitrexed (USAN List No. 389). 1996;60:701

Raluridine

Raluridine (USAN List No. 389). 1996;60:701

Receptors, adrenergic, alpha

The effects of the menstrual cycle, race, and gender on adrenergic receptors and agonists (Mills et al). 1996;60:99-104

Receptors, adrenergic, beta

The effects of the menstrual cycle, race, and gender on adrenergic receptors and agonists (Mills et al). 1996;60:99-104

Receptors, endothelin

Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects (Weber et al). 1996;60:124-37

Renal failure, chronic; see Kidney failure, chronic

Research

Factors often not considered before a multicenter trial is started (Hardy). 1996;60:121-3 (Commentary)

Reserpine

Reserpine: a tragic victim of myths, marketing, and fashionable prescribing (Fraser). 1996;60:368-73 (Commentary)

Resocortol butyrate

Resocortol butyrate (USAN List No. 384). 1996;60:118

Reviewers

List of reviewers. 1996;60:479

Rismorelin porcine

Rismorelin porcine (USAN List No. 384). 1996;60:120

Ritonavir

Ritonavir (USAN List No. 384). 1996;60:118

Rizatriptan benzoate

Rizatriptan benzoate (USAN List No. 387). 1996;60:482

Rizatriptan sulfate

Rizatriptan sulfate (USAN List No. 387). 1996;60:481

S

Salt

Dietary salt restriction increases vascular insulin resistance (Feldman et al). 1996;60:444-51

Samarium Sm 153 lexitronam pentasodium

Samarium Sm 153 lexitronam pentasodium (USAN List No. 384). 1996;60:119

Sertraline

The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin (Hamelin et al). 1996;60:512-21

Smoking cessation

The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain (Nørregaard et al). 1996;60:679-86

Efficacy of buspirone in smoking cessation: a placebo-controlled trial (Schneider et al). 1996;60:568-75

Stress

Cardiovascular adaptation to orthostatic stress during vasodilator therapy (Lipsitz et al). 1996;60:461-71

Substance P

Substance P in human hand veins in vivo: tolerance, efficacy, potency, and mechanism of venodilator action (Strobel et al). 1996;60:435-43

Sumatriptan

Cerebral and ocular hemodynamic effects of sumatriptan in the nitroglycerin headache model (Schmetterer et al). 1996;60:199-205

Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response (Visser et al). 1996;60:452-60

T

Telnavir

Telnavir (USAN List No. 384). 1996;60:116

Temperature

Exposure to high ambient temperature increases absorption and plasma concentrations of transdermal nicotine (Vanakoski et al). 1996;60:308-15

Terodiline

Stereoselective cardiotoxic effects of terodiline (Hartigan-Go et al). 1996;60:89-98

Thiopurine

Thiopurine methyltransferase activity in a Korean population sample of children (Park-Hah et al). 1996;60:68-74

Thioridazine

Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans (Hartigan-Go et al). 1996;60:543-53

Thymalfasin

Thymalfasin (USAN List No. 384). 1996;60:119

Time factors

The effect of ingestion time interval on the interaction between itraconazole and triazolam (Neuvonen et al). 1996;60:326-31

Tissue-type plasminogen activator; see Plasminogen activator, tissue-type

Tramadol

The hypoalgesic effect of tramadol in relation to CYP2D6 (Poulsen et al). 1996;60:636-44

Tranquilizing agents, major

Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans (Hartigan-Go et al). 1996;60:543-53

Transdermal administration; see Administration, cutaneous

Triazolam

The effect of ingestion time interval on the interaction between itraconazole and triazolam (Neuvonen et al). 1996;60:326-31

U

United States Adopted Names Council

Notice of an addition to the USAN guiding principles. 1996;60:239
USAN Council. 1996;60:116-20, 237-9, 361-2, 481-4, 599-60, 700-2

Urine

Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers (Chen et al). 1996;60:651-60

V

Valproate

Bidirectional interaction of valproate and lamotrigine in healthy subjects (Anderson et al). 1996;60:145-56

Valsartan

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine (Corea et al). 1996;60:341-6

Vancomycin

Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies (Fernández de Gatta et al). 1996;60:332-40

Vasodilation

Abnormal desmopressin-induced forearm vasodilatation in patients with heart failure: dependence on nitric oxide synthase activity (Rector et al). 1996;60:667-74

Morphine-induced venodilation in humans (Grossmann et al). 1996;60:554-60

Substance P in human hand veins in vivo: tolerance, efficacy, potency, and mechanism of venodilator action (Strobel et al). 1996;60:435-43

Vasodilators

Cardiovascular adaptation to orthostatic stress during vasodilator therapy (Lipsitz et al). 1996;60:461-71

Veins

Morphine-induced venodilation in humans (Grossmann et al). 1996;60:554-60

Substance P in human hand veins in vivo: tolerance, efficacy, potency, and mechanism of venodilator action (Strobel et al). 1996;60:435-43

Volunteer screening

Medical histories may be unreliable in screening volunteers for clinical trials (Apseloff et al). 1996;60:353-6

W**Watercress**

Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers (Chen et al). 1996;60:651-60

Weight gain

The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain (Nørregaard et al). 1996;60:679-86

X**Xemilofiban hydrochloride**

Xemilofiban hydrochloride (USAN List No. 384). 1996;60:120

Z**Zidovudine**

Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus (Peter and Gambertoglio). 1996;60:168-76

Zoledronate disodium

Zoledronate disodium (USAN List No. 387). 1996;60:482

Zoledronate trisodium

Zoledronate trisodium (USAN List No. 387). 1996;60:482

Zoledronic acid

Zoledronic acid (USAN List No. 387). 1996;60:483

